<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations and diagnosis of allergic bronchopulmonary aspergillosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations and diagnosis of allergic bronchopulmonary aspergillosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations and diagnosis of allergic bronchopulmonary aspergillosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Praveen Akuthota, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter F Weller, MD, MACP</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carol A Kauffman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Barnes, DM, DSc, FRCP, FRS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 18, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Allergic bronchopulmonary aspergillosis (ABPA) is a complex hypersensitivity reaction in response to colonization of the airways with <em>Aspergillus fumigatus</em> that occurs almost exclusively in patients with asthma or cystic fibrosis (CF) [<a href="#rid1">1-4</a>]. In chronic cases, repeated episodes of bronchial obstruction, inflammation, and mucoid impaction can lead to bronchiectasis, fibrosis, and respiratory compromise [<a href="#rid5">5</a>]. </p><p>The pathophysiology, clinical manifestations, and diagnosis of ABPA will be reviewed here. The management of ABPA and general issues related to bronchiectasis are discussed separately. (See  <a class="medical medical_review" href="/d/html/104431.html" rel="external">"Treatment of allergic bronchopulmonary aspergillosis"</a> and  <a class="medical medical_review" href="/d/html/1444.html" rel="external">"Clinical manifestations and diagnosis of bronchiectasis in adults"</a> and  <a class="medical medical_review" href="/d/html/1435.html" rel="external">"Bronchiectasis in adults: Treatment of acute and recurrent exacerbations"</a>.)</p><p class="headingAnchor" id="H1161311852"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The prevalence of allergic bronchopulmonary aspergillosis (ABPA) among patients with persistent asthma is estimated at 1 to 2 percent, although rates up to 28 percent have been reported [<a href="#rid1">1,4,6</a>]. Reported rates are higher in patients seen in asthma clinics and those admitted to the hospital with an asthma exacerbation [<a href="#rid4">4</a>]. Among patients with cystic fibrosis, reported prevalences range from 2 to 9 percent [<a href="#rid1">1,5,7-10</a>].</p><p>Rarely, ABPA occurs in patients with bronchiectasis, chronic granulomatous disease, hyperimmunoglobulinemia E, and in lung transplant recipients [<a href="#rid4">4,11-13</a>].</p><p class="headingAnchor" id="H2"><span class="h1">PATHOLOGY AND PATHOGENESIS</span><span class="headingEndMark"> — </span>Allergic bronchopulmonary aspergillosis (ABPA) is characterized pathologically by mucoid impaction of the bronchi, eosinophilic pneumonia, and bronchocentric granulomatosis in addition to the histologic features of asthma [<a href="#rid5">5,14</a>]. Areas of eosinophilic pneumonia are occasionally found, although not a major feature of the disease [<a href="#rid15">15</a>]. Septated hyphae with acute dichotomous branching may be seen in the mucus-filled bronchial lumen, but fungi do not invade the mucosa. <em>Aspergillus</em> is cultured from the sputum in up to two-thirds of patients with ABPA, but hyphae may not be seen by direct microscopy. (See  <a class="medical medical_review" href="/d/html/4322.html" rel="external">"Bronchocentric granulomatosis"</a>.)</p><p>The pathogenesis of ABPA remains incompletely understood [<a href="#rid5">5,14</a>]. There is no relation between the intensity of exposure to airborne <em>Aspergillus</em> spores and rates of sensitization to the fungus as measured by skin testing [<a href="#rid16">16</a>]. Although all spores that are inhaled in sufficient quantities can behave as allergens, the normally low level of IgG against fungal antigens in the circulation and the low antifungal secretory IgA in bronchoalveolar fluid suggest that healthy individuals are able to effectively eliminate fungal spores [<a href="#rid17">17,18</a>]. In contrast, exposure of atopic individuals to fungal spores or mycelial fragments results in the formation of IgE and IgG antibodies.</p><p>T cells also play an important role in ABPA. There are increases in Th2 CD4+ cell responses to <em>Aspergillus</em> antigens both in the bronchoalveolar lymphoid tissue and systemically [<a href="#rid5">5</a>]. <em>Aspergillus</em>-responsive T cells generate cytokines interleukin (IL)-4, IL-5, and IL-13, which in turn account for the increases in blood and airway eosinophils and IgE in ABPA. In one study, T cell clones specific to the Asp f 1 antigen of <em>A. fumigatus</em> were established from the peripheral blood of three patients with ABPA [<a href="#rid19">19</a>]. The majority of these clones were CD4+ cells of the Th2 phenotype, which produce IL-4 and IL-5 [<a href="#rid19">19</a>]. The response to the Asp f 1 antigen was HLA restricted, being mediated exclusively by either HLA-DR2 or HLA-DR5 and was restricted to specific T cell receptor V-beta chains [<a href="#rid19">19</a>]. In addition, there is increased sensitivity of B cells, T cells, NK cells, and eosinophils to IL-4 [<a href="#rid5">5</a>]. Single nucleotide polymorphisms in IL-13, IL-4 receptor, and toll like receptor (TLR)-3 have been identified in patients with ABPA in comparison to those with atopic asthma [<a href="#rid20">20</a>].</p><p>In another study, the costimulatory molecule OX40 ligand was crucial for driving Th2 responses to <em>A. fumigatus</em> in the CD4+ cells of patients with cystic fibrosis (CF) and ABPA [<a href="#rid21">21</a>]. Heightened Th2 reactivity in these patients correlated with lower mean serum vitamin D levels.</p><p><em>Aspergillus </em>colonization of the asthmatic airway leads to vigorous IgE- and IgG-mediated immune responses superimposed on the asthmatic milieu. In spite of these vigorous responses in ABPA, the fungus is able to colonize the airway and cause recurrent symptoms. Proteolytic enzymes and mycotoxins released by fungi, in concert with Th2-mediated eosinophilic inflammation and IL-8-mediated neutrophilic inflammation [<a href="#rid22">22</a>], may result in airway damage and central bronchiectasis. Eosinophil extracellular traps have been noted in the airway mucous in ABPA patients and may be an additional mediator of ABPA pathobiology [<a href="#rid23">23</a>].</p><p>Th17-mediated pathology may have a key role in ABPA and may be further driven by Th17 cell cross-reactivity with <em>Candida</em>-derived antigens [<a href="#rid24">24</a>]. Specifically, <em>Aspergillus</em>-specific Th17 cells can be isolated in the blood during acute exacerbations of ABPA prior to treatment, and these cells demonstrate high cross-reactivity with <em>C. albicans</em>.</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Allergic bronchopulmonary aspergillosis (ABPA) occurs primarily in patients with asthma (1 to 5 percent of asthma patients) or cystic fibrosis (CF; 1 to 9 percent of CF patients) [<a href="#rid10">10,25</a>]. (See <a class="local">'Epidemiology'</a> above.)</p><p class="headingAnchor" id="H1248738776"><span class="h2">Signs and symptoms</span><span class="headingEndMark"> — </span>The clinical picture of ABPA is dominated by asthma and recurrent exacerbations. In severe cases, episodes of bronchial obstruction, fever, malaise, expectoration of brownish mucus plugs, and, at times, hemoptysis may occur. Wheezing is not always evident, and some patients present with asymptomatic pulmonary consolidation.</p><p>A minority of patients with ABPA have concomitant allergic aspergillus rhinosinusitis with symptoms of nasal congestion/obstruction, sinus pressure, and thick, dark-colored nasal discharge [<a href="#rid26">26,27</a>]. Allergic fungal rhinosinusitis is discussed separately. (See  <a class="medical medical_review" href="/d/html/101017.html" rel="external">"Allergic fungal rhinosinusitis"</a>.)</p><p class="headingAnchor" id="H1248738880"><span class="h2">Laboratory</span><span class="headingEndMark"> — </span>Laboratory abnormalities in ABPA include an elevated total blood eosinophil count (generally &gt;500 cells/microL), elevated total serum IgE (generally &gt;1000 IU/mL), specific IgE to <em>Aspergillus</em> on immunoassay, and specific IgG antibodies or precipitating IgG antibodies (precipitins) to <em>Aspergillus</em> [<a href="#rid26">26,28,29</a>]. However, elevated blood eosinophils and total IgE can be caused by a variety of processes  (<a class="graphic graphic_table graphicRef76875" href="/d/graphic/76875.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef83457" href="/d/graphic/83457.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/5540.html" rel="external">"Overview of in vitro allergy tests"</a> and  <a class="medical medical_review" href="/d/html/100544.html" rel="external">"Eosinophil biology and causes of eosinophilia", section on 'Major causes of eosinophilia'</a>.)</p><p>Expectorated sputum may contain "plugs" with eosinophils, Charcot-Leyden crystals, and may grow <em>Aspergillus</em> in culture [<a href="#rid15">15</a>].</p><p>Serum galactomannan is not useful in the identification of ABPA [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Imaging</span><span class="headingEndMark"> — </span>Central bronchiectasis is a frequent feature of ABPA and affects airways in the central one-half to two-thirds of the chest on imaging studies. Evidence of mucus plugging may be present on chest imaging as well. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chest radiograph</strong> – The chest radiograph may show parenchymal opacities (usually involving the upper lobes), atelectasis due to mucoid impaction, and a number of findings characteristic of bronchiectasis [<a href="#rid31">31</a>] (see  <a class="medical medical_review" href="/d/html/1444.html" rel="external">"Clinical manifestations and diagnosis of bronchiectasis in adults"</a>). These include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>"Tram line" shadows due to thickened walls of nondilated bronchi</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>"Parallel lines" due to the presence of ectatic bronchi</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>"Ring shadows" due to bronchial wall thickening or saccular bronchiectasis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>"Toothpaste shadows" due to mucoid impacted second- to fourth-order bronchi</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>"Gloved finger shadows" due to intrabronchial exudates with bronchial wall thickening; these appear as branched tubular radiodensities 2 to 3 cm long and 5 to 8 mm wide that extend from the hilus.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Perihilar opacities due to mucus plugging may mimic hilar adenopathy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High-resolution computed tomography</strong> – The high-resolution computed tomography (HRCT) scan of the thorax may show widespread proximal cylindrical bronchiectasis with upper lobe predominance and bronchial wall thickening  (<a class="graphic graphic_diagnosticimage graphicRef64077" href="/d/graphic/64077.html" rel="external">image 1</a>). However, central bronchiectasis (affecting medial one-half to two-thirds of the lungs) with normal tapering of distal bronchi has not been a consistently sensitive or specific marker for ABPA in all series [<a href="#rid31">31-36</a>]. In a series of 110 patients with ABPA, 24 (22 percent) had a normal HRCT, while 86 (78 percent) had central bronchiectasis mostly affecting the middle and upper lobes [<a href="#rid37">37</a>]. In a separate series of 15 patients, the sensitivity of central bronchiectasis on chest computed tomography (CT) as a diagnostic feature for ABPA was only 37 percent [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/d/html/6988.html" rel="external">"High resolution computed tomography of the lungs", section on 'Airways diseases'</a>.)</p><p></p><p class="bulletIndent1">In addition to bronchiectasis, other findings on HRCT include nodules, mucus plugging, tree-in-bud opacities, high attenuation mucus, atelectasis, peripheral airspace consolidation, or ground-glass attenuation, and possibly mosaic perfusion or air trapping [<a href="#rid33">33,35,37</a>]. High attenuation mucus, defined as mucus that is radiographically denser than skeletal muscle, is seen in 18 to 28 percent of patients with ABPA [<a href="#rid37">37-39</a>]. Using these criteria, in comparison with other forms of eosinophilic lung diseases, radiologists made a correct diagnosis of ABPA in 84 percent of cases [<a href="#rid33">33</a>]. Coordination between clinical and CT findings are advised to optimize the diagnosis of ABPA [<a href="#rid33">33</a>].</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Pulmonary function testing</span><span class="headingEndMark"> — </span>Most patients have airflow obstruction and air trapping with a reduced forced expiratory volume in one second (FEV<sub>1</sub>) and increased residual volume; a positive bronchodilator response is found in less than one-half of patients [<a href="#rid40">40</a>]. </p><p>Individuals with bronchiectasis or fibrosis may exhibit a mixed obstructive and restrictive pattern. A minority of patients has a reduction in diffusing capacity, an abnormality that may be more common in the presence of bronchiectasis [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H9"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>There is no individual test that establishes the diagnosis of allergic bronchopulmonary aspergillosis (ABPA), nor is there a single set of agreed upon diagnostic criteria [<a href="#rid1">1,5,14,26,41</a>]. The diagnosis is suspected in patients with asthma with recurrent exacerbations; a chest radiograph showing mucus plugging, upper or middle lobe consolidation, or central bronchiectasis; an eosinophil count &gt;500/m<sup>3</sup>; or a total IgE &gt;417 IU/mL [<a href="#rid38">38</a>]. The diagnosis is based on establishing allergic sensitization to <em>Aspergillus</em> antigens in the proper clinical and radiographic context.</p><p class="headingAnchor" id="H168247056"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>Although not prospectively validated, we favor the following diagnostic criteria proposed by the International Society for Human and Animal Mycology (ISHAM) working group for ABPA that simplify prior diagnostic schema  (<a class="graphic graphic_table graphicRef104812" href="/d/graphic/104812.html" rel="external">table 3</a>) [<a href="#rid42">42</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Predisposing conditions (one must be present): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Asthma </p><p class="bulletIndent2"><span class="glyph">•</span>Cystic fibrosis (CF)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Obligatory criteria (both must be present):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Detectable serum IgE levels against <em>Aspergillus fumigatus</em> (&gt;0.35 kU/L) <strong>or</strong> <em>Aspergillus</em> skin test positivity</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Elevated total serum IgE concentration (typically &gt;1000 IU/mL, but if the patient meets all other criteria, an IgE value &lt;1000 IU/mL may be acceptable, especially if serum <em>Aspergillus fumigatus</em>-specific IgG levels are &gt;27 mg/L)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other criteria (at least two must be present):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Precipitating serum antibodies to <em>A. fumigatus </em>or elevated <em>Aspergillus fumigatus</em>-specific IgG levels (&gt;27 mg/L) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Radiographic pulmonary opacities consistent with ABPA (see <a class="local">'Imaging'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Total eosinophil count &gt;500 cells/microL in glucocorticoid-naïve patients (may be historical)</p><p></p><p>ABPA without asthma or CF is a rare occurrence [<a href="#rid43">43-45</a>]. One series described 11 such patients with ABPA who did not have asthma by history and who had negative bronchodilator responsiveness [<a href="#rid43">43</a>]. Some of these individuals subsequently developed asthma, suggesting that they were diagnosed during a preclinical phase of disease. Three of the 11 patients had hypersensitivity to fungi other than <em>Aspergillus</em>, and differences in the host responses to these pathogens may have accounted for the absence of clinical asthma. In a separate series of 530 patients with ABPA, 37 (7 percent) had ABPA without asthma [<a href="#rid45">45,46</a>]. While these patients were not evaluated for CF, they did have fewer exacerbations and better spirometry than those with ABPA associated with asthma. As examples, COPD and post-tuberculous fibrocavitary disease may predispose to ABPA [<a href="#rid42">42</a>]. </p><p class="headingAnchor" id="H10"><span class="h2">Step-wise evaluation</span><span class="headingEndMark"> — </span>A step-wise evaluation of possible ABPA typically proceeds through the following tests, although the sequence may vary based on the clinical suspicion and results of previous tests:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immediate skin test to </strong><strong><em>Aspergillus</em></strong> <strong>and/or specific serum IgE </strong>– The choice of test to establish the presence of IgE specific to <em>Aspergillus</em> antigens in an asthmatic being evaluated for ABPA will depend partially on the resources available. A negative prick skin test followed by negative intradermal reactivity to <em>Aspergillus</em> virtually excludes ABPA from consideration. Extremely rarely, allergic bronchopulmonary mycosis is diagnosed in a patient with a negative testing for <em>Aspergillus</em>. (See <a class="local">'Diagnosis of allergic bronchopulmonary mycosis'</a> below.)</p><p></p><p class="bulletIndent1">The presence of at least a two-fold elevation in specific anti-<em>Aspergillus</em> IgE compared with pooled serum of <em>Aspergillus</em>-sensitized non-ABPA asthmatics has been suggested to distinguish seropositive ABPA from sensitization to <em>Aspergillus</em> in asthmatics without ABPA. However, given that clinical practice does not readily allow for such a comparison with pooled controls, we use the cut-off of 0.35 kU/L suggested by the ISHAM working group [<a href="#rid26">26,42</a>]. Such an approach allows for the use of commercially available semi-quantitative immunoassays in applying these criteria.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum total IgE and peripheral eosinophil count</strong> – If the immediate skin test or specific IgE is positive, serum total IgE should be checked if it hasn’t been checked already. Many clinicians obtain the total serum IgE concurrently with <em>Aspergillus</em>-specific IgE, which allows for complete evaluation for the ISHAM obligatory criteria  (<a class="graphic graphic_table graphicRef104812" href="/d/graphic/104812.html" rel="external">table 3</a>) [<a href="#rid42">42</a>]. IgE levels, similar to blood eosinophilia, may decrease if the patient is receiving systemic glucocorticoids, but generally do not normalize.</p><p></p><p class="bulletIndent1">The issue of the appropriate cutoff value of total serum IgE concentration for a diagnosis of ABPA is a source of some confusion. Although there is no single value that has been found to define ABPA, various sources have used 417 IU/mL (1000 ng/mL) and 1000 IU/mL [<a href="#rid1">1,4</a>]. Further complicating matters are criteria from the Cystic Fibrosis Foundation Consensus Conference for establishing a diagnosis of ABPA in CF which use a total IgE cutoff of &gt;500 IU/mL [<a href="#rid5">5</a>]. Until further studies are published, we recommend using the ISHAM value of total IgE &gt;1000 IU/mL, with an allowance for a lower value if all other criteria are met. Total IgE values in ABPA may range as high as 25,000 IU/mL.</p><p></p><p class="bulletIndent1">Patients with ABPA typically have an elevated total eosinophil count of at least &gt;500/mm<sup>3</sup> and often &gt;1000/mm<sup>3</sup>. While there is no upper limit established for the peripheral eosinophilia observed in ABPA, it is our opinion that clinicians should be particularly attuned to the possibility of alternative diagnoses featuring systemic eosinophilia, such as eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss) and the hypereosinophilic syndromes, at values &gt;2000 /mm<sup>3 </sup> (<a class="graphic graphic_table graphicRef83457" href="/d/graphic/83457.html" rel="external">table 2</a>).<sup> </sup></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chest imaging</strong> – While a chest radiograph can be useful in detecting abnormalities related to ABPA as described above, chest CT has become the modality of choice in evaluating patients suspected of having ABPA, particularly given the need to evaluate for bronchiectasis with a more sensitive test. (See <a class="local">'Imaging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precipitating </strong><strong><em>Aspergillus</em></strong><strong> antibodies </strong>– The detection of Aspergillus serum precipitins continues to have clinical utility in the diagnosis of ABPA [<a href="#rid26">26</a>]. Newer immunoassays can be used to detect or confirm specific IgG antibodies against Aspergillus antigens and may be more sensitive than serum precipitins [<a href="#rid26">26,46-48</a>]. Once documented as positive, precipitating antibodies are not followed or used for monitoring. </p><p></p><p class="headingAnchor" id="H1835270507"><span class="h2">Diagnosis of allergic bronchopulmonary mycosis</span><span class="headingEndMark"> — </span>Rarely, an ABPA-like syndrome will be caused by a fungus other than <em>Aspergillus fumigatus</em> and is termed allergic bronchopulmonary mycosis (ABPM). The list of implicated fungi is long and includes fungi such as <em>Aspergillus</em> species (eg, <em>A. flavus</em>, <em>A. niger</em>, <em>A. oryzae</em>, <em>A. ochraceus</em>), <em>Candida</em>, <em>Helminthosporium</em>, <em>Penicillium</em>, <em>Bipolaris</em>, <em>Scedosporium</em>, and others [<a href="#rid4">4,49-52</a>]. Patients present with clinical features of ABPA (eg, mucus plugging, eosinophilia, elevated serum total IgE), but negative skin tests and serologic studies. The diagnosis is generally suspected after isolation of one of these other agents from sputum cultures or based upon documented exposure (eg, <em>A. oryzae</em> in a soy sauce factory). Support for a diagnosis of ABPM comes from demonstration of positive specific IgE and IgG antibodies to the alternative fungus and/or positive precipitins.</p><p class="headingAnchor" id="H12"><span class="h2">Diagnosis of ABPA in cystic fibrosis</span><span class="headingEndMark"> — </span>It can be difficult to establish the diagnosis of ABPA in patients with CF due to shared symptoms and often complex radiographic features, including productive cough, wheeze, and bronchiectasis [<a href="#rid5">5,26,53</a>]. We follow the criteria for the diagnosis of ABPA in patients with CF that were formulated by the International Society for Human and Animal Mycology (ISHAM) working group for ABPA, which are similar to previous criteria of the Cystic Fibrosis Foundation Consensus Conference (CFCC)  (<a class="graphic graphic_table graphicRef104812" href="/d/graphic/104812.html" rel="external">table 3</a>) [<a href="#rid5">5,26</a>].</p><p>Bronchiectasis and recurrent pulmonary infections are typical of CF, but ABPA should be suspected in patients with pulmonary opacities or clinical deterioration that do not respond to one week of antibiotic treatment [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/d/html/6369.html" rel="external">"Cystic fibrosis: Clinical manifestations of pulmonary disease"</a>.)</p><p>The CFCC guidelines for screening for ABPA in CF include [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Maintain a high level of suspicion for ABPA in CF patients &gt;6 years of age, particularly those with clinical deterioration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Determine the serum total IgE concentration annually. If the concentration is &gt;500 IU/mL (&gt;1200 ng/mL), evaluate for anti-<em>Aspergillus</em> IgE by determining skin test reactivity or serum immunoassay for IgE to <em>A. fumigatus</em>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the serum IgE is 200 to 500 IU/mL (480 to 1200 ng/mL), repeat the measurement if there is increased clinical suspicion of ABPA and perform further diagnostic tests (eg, skin tests to <em>Aspergillus</em> antigen, in vitro tests for anti-<em>Aspergillus fumigatus</em> IgE, IgG and precipitins, chest radiograph).</p><p></p><p>Though not in routine use, measurement of basophil activation by assaying levels of the surface marker CD203c by flow cytometry in response to <em>Aspergillus</em> extract stimulation may be useful in the diagnosis of ABPA in patients with cystic fibrosis [<a href="#rid54">54-56</a>]. </p><p>ABPA must be differentiated from invasive aspergillus infection as patients with CF appear to be at increased risk for this complication due to risk factors such as nutritional deficiency, diabetes mellitus, and chronic/frequent antibiotic therapy [<a href="#rid53">53</a>]. ABPA and other semi-invasive manifestations of <em>Aspergillus</em> infection (eg, bronchial aspergillosis, wound or anastomotic infection) can also occur after lung transplantation for CF [<a href="#rid57">57</a>]. (See  <a class="medical medical_review" href="/d/html/15717.html" rel="external">"Diagnosis of invasive aspergillosis"</a> and  <a class="medical medical_review" href="/d/html/1394.html" rel="external">"Fungal infections following lung transplantation"</a> and  <a class="medical medical_review" href="/d/html/2441.html" rel="external">"Chronic pulmonary aspergillosis: Epidemiology, clinical manifestations and diagnosis", section on 'Diagnosis'</a>.) </p><p class="headingAnchor" id="H1150172384"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of allergic bronchopulmonary aspergillosis (ABPA) largely centers on considering other entities characterized by peripheral eosinophilia and pulmonary abnormalities, including asthma with <em>Aspergillus</em> sensitization, bronchocentric granulomatosis, eosinophilic granulomatosis with polyangiitis, and pulmonary eosinophilia due to drugs or parasitic infection, and chronic pulmonary aspergillosis. (See  <a class="medical medical_review" href="/d/html/5691.html" rel="external">"Approach to the patient with unexplained eosinophilia"</a> and  <a class="medical medical_review" href="/d/html/5715.html" rel="external">"Overview of pulmonary eosinophilia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asthma with fungal sensitization</strong> – ABPA is frequently raised as a diagnostic possibility in patients with asthma, particularly if immediate skin test reactivity to <em>Aspergillus</em> is present. Estimates of the frequency of ABPA among asthmatics vary considerably. As examples, a university tertiary care allergy clinic with special interest in ABPA ultimately diagnosed ABPA in 6 percent of asthmatics with immediate reactivity to <em>Aspergillus</em>, but ABPA has been documented in up to 32 percent of patients with asthma and skin test reactivity to <em>Aspergillus</em> in other series [<a href="#rid25">25,58-61</a>].</p><p></p><p class="bulletIndent1">Many asthmatics have one or more findings of ABPA but do not meet full criteria for the diagnosis. Features of ABPA which are found commonly in asthmatics <strong>without </strong>ABPA include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Positive immediate skin reactivity to <em>A. fumigatus</em>, which is present in 20 to 30 percent of all asthmatics [<a href="#rid59">59,62</a>]. The label "severe asthma with fungal sensitization" has been used to describe such patients, as well as those with skin test reactivity to other fungal antigens. (See  <a class="medical medical_review" href="/d/html/104431.html" rel="external">"Treatment of allergic bronchopulmonary aspergillosis", section on 'Acute ABPA'</a> and  <a class="medical medical_review" href="/d/html/104431.html" rel="external">"Treatment of allergic bronchopulmonary aspergillosis", section on 'Treatment'</a>.) .</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Positive serum precipitins to <em>Aspergillus</em>, which occur in 10 percent of asthmatics without ABPA and in 10 percent of nonasthmatic patients with chronic lung disease [<a href="#rid63">63,64</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Recurrent mucoid impaction and atelectasis, particularly among poorly controlled asthmatics</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Peripheral blood eosinophilia and elevation of serum total IgE</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bronchiectasis is present on HRCT in 15 to 18 percent of non-ABPA asthmatics with positive immediate skin reactivity to <em>Aspergillus </em>[<a href="#rid65">65-67</a>]. One report compared 17 patients with ABPA to 11 with asthma and a positive skin test to <em>A. fumigatus</em> but not other features of ABPA [<a href="#rid67">67</a>]. Bronchiectasis by CT scan was much more common in the patients with ABPA (42 versus 5 percent of lobes). </p><p></p><p class="bulletIndent1">ABPA likely lies on the same spectrum of illness as asthma with fungal sensitization, which makes distinguishing these entities from one another challenging, particularly with respect to identifying disease-defining total and specific IgE values.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary eosinophilia</strong> — A broad spectrum of diseases other than ABPA can cause pulmonary eosinophilia  (<a class="graphic graphic_table graphicRef76875" href="/d/graphic/76875.html" rel="external">table 1</a>). A negative prick skin test and the absence of precipitins to <em>Aspergillus</em> virtually exclude ABPA and should prompt evaluation of other diagnostic possibilities. (See  <a class="medical medical_review" href="/d/html/5715.html" rel="external">"Overview of pulmonary eosinophilia"</a>.)</p><p></p><p class="bulletIndent1">Diseases to consider in patients with radiographic opacities and eosinophilia in the peripheral blood or bronchoalveolar lavage include the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute or chronic eosinophilic pneumonia (see  <a class="medical medical_review" href="/d/html/4374.html" rel="external">"Idiopathic acute eosinophilic pneumonia", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/4360.html" rel="external">"Chronic eosinophilic pneumonia", section on 'Diagnosis'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Drug or toxin-induced eosinophilic pneumonia (see  <a class="medical medical_review" href="/d/html/5715.html" rel="external">"Overview of pulmonary eosinophilia", section on 'Medications and toxins'</a> and  <a class="medical medical_review" href="/d/html/4343.html" rel="external">"Pulmonary complications of cocaine use", section on 'Acute eosinophilic pneumonia'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypereosinophilic syndromes (see  <a class="medical medical_review" href="/d/html/2211.html" rel="external">"Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tropical eosinophilic pneumonia (see  <a class="medical medical_review" href="/d/html/5711.html" rel="external">"Tropical pulmonary eosinophilia"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Loeffler's pneumonia </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Eosinophilic granulomatosis with polyangiitis<strong> – </strong>Like ABPA, patients with eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss) can present with the combination of asthma, eosinophilia, and radiographic opacities. Features favoring a diagnosis of EGPA include a positive serum antineutrophil cytoplasmic antibody (ANCA), skin lesions, mononeuropathy, or other extrapulmonary manifestation of vasculitis. (See  <a class="medical medical_review" href="/d/html/4347.html" rel="external">"Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)", section on 'Diagnostic criteria'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bronchiectasis</strong> – Patients with bronchiectasis should be evaluated for ABPA unless the patient has clear alternative cause. Although central bronchiectasis is often seen in ABPA, it is a nonspecific finding. As an example, one series of 168 patients found that CT characteristics of bronchiectasis failed to differentiate disease caused by ABPA from that due to hypogammaglobulinemia, ciliary dysfunction, cystic fibrosis (CF), or idiopathic causes [<a href="#rid32">32</a>]. The bronchiectasis was more likely to be widespread and central in ABPA than in other causes, but these findings were not predictive in the individual patient. (See  <a class="medical medical_review" href="/d/html/1444.html" rel="external">"Clinical manifestations and diagnosis of bronchiectasis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic pulmonary aspergillosis</strong> – "Chronic cavitary pulmonary aspergillosis (CCPA)" is characterized by formation and expansion of one or more pulmonary cavities over several months in an immunocompetent patient. Aspergillus precipitins or specific IgG antibodies may be present in the serum; galactomannan is present in the bronchoalveolar lavage fluid in 50 to 90 percent of patients. Aspergillus-specific IgE may also be present, along with a slightly elevated total serum IgE. Aspergillomas may be present. (See  <a class="medical medical_review" href="/d/html/2441.html" rel="external">"Chronic pulmonary aspergillosis: Epidemiology, clinical manifestations and diagnosis", section on 'Chronic cavitary pulmonary aspergillosis (CCPA)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mucoid impaction and bronchocentric granulomatosis </strong>– Mucoid impaction and bronchocentric granulomatosis are commonly seen as components of ABPA. However, approximately half the cases of bronchocentric granulomatosis are not associated with ABPA. As bronchocentric granulomatosis is considered a nonspecific response to airway injury, a careful search for an underlying cause (eg, ABPA, mycobacterial and fungal infection, rheumatoid arthritis, granulomatosis with polyangiitis, bronchogenic carcinoma) should be undertaken. (See  <a class="medical medical_review" href="/d/html/4322.html" rel="external">"Bronchocentric granulomatosis"</a>.)</p><p></p><p class="headingAnchor" id="H1236924023"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>Complications of allergic bronchopulmonary aspergillosis (ABPA) include acute invasive pulmonary aspergillosis [<a href="#rid68">68</a>], aspergilloma [<a href="#rid4">4,69</a>], chronic pulmonary aspergillosis [<a href="#rid70">70</a>], and the panoply of problems related to bronchiectasis. </p><p>Acute invasive pulmonary aspergillosis is a rare complication of ABPA and can occur during <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> therapy. At least nine such cases have been reported [<a href="#rid68">68</a>]. Acute invasive pulmonary aspergillosis in this setting can be fulminant, possibly due to the immunosuppressive effect of systemic glucocorticoids. (See  <a class="medical medical_review" href="/d/html/2454.html" rel="external">"Epidemiology and clinical manifestations of invasive aspergillosis"</a>.)</p><p>A few case reports have described the development of an aspergilloma in patients with ABPA [<a href="#rid4">4,69</a>].</p><p>Central bronchiectasis is a well-known complication of ABPA and can result in recurrent bacterial infections, hemoptysis, and chronic respiratory insufficiency. (See  <a class="medical medical_review" href="/d/html/1444.html" rel="external">"Clinical manifestations and diagnosis of bronchiectasis in adults"</a>.)</p><p class="headingAnchor" id="H2557038890"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109727.html" rel="external">"Society guideline links: Aspergillosis"</a>.)</p><p class="headingAnchor" id="H1700185"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/83427.html" rel="external">"Patient education: Allergic bronchopulmonary aspergillosis (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H20"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Background</strong> – Allergic bronchopulmonary aspergillosis (ABPA) is a complex hypersensitivity reaction of the airways that occurs when bronchi become colonized by <em>Aspergillus</em> species. ABPA most commonly develops in patients with asthma, but can also develop in patients with cystic fibrosis. Repeated episodes of bronchial obstruction, inflammation, and mucoid impaction can lead to bronchiectasis, fibrosis, and respiratory compromise. (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathology</strong> – ABPA is characterized pathologically by mucoid impaction of the bronchi, eosinophilic pneumonia, and bronchocentric granulomatosis in addition to the histologic features of asthma. Septated hyphae with acute dichotomous branching may be seen in the mucus-filled bronchial lumen, but fungi rarely invade the mucosa. (See <a class="local">'Pathology and pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – The clinical picture of ABPA is dominated by asthma and recurrent exacerbations. In severe cases, episodes of bronchial obstruction, fever, malaise, expectoration of brownish mucus plugs, and, at times, hemoptysis may occur. Imaging features may include mucus plugging (often with high attenuation mucus) and central bronchiectasis (affects inner one-half to two-thirds of lung). (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic criteria</strong> – There is no individual test to establish the diagnosis of ABPA. The diagnosis is usually confirmed by use of a combination of clinical, radiographic, and immunologic criteria. We favor the following diagnostic criteria proposed by the International Society for Human and Animal Mycology (ISHAM) working group that simplify prior diagnostic schema  (<a class="graphic graphic_table graphicRef104812" href="/d/graphic/104812.html" rel="external">table 3</a>). (See <a class="local">'Diagnostic criteria'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation – </strong>Establishing IgE sensitization to Aspergillus through either skin prick test or measurement of specific serum IgE is a reasonable first step in an asthmatic being evaluated for ABPA. Inability to establish IgE sensitization to <em>Aspergillus</em> virtually excludes ABPA from consideration. If skin testing and/or specific IgE are positive, total serum IgE, precipitins to <em>Aspergillus, </em>and eosinophil count should be assayed. Chest imaging, preferably with a chest CT, should be performed to assess presence and severity of bronchiectasis. (See <a class="local">'Step-wise evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis </strong>– The differential diagnosis of allergic bronchopulmonary aspergillosis (ABPA) largely focuses on entities characterized by peripheral eosinophilia and pulmonary abnormalities, including asthma with <em>Aspergillus</em> sensitization, bronchocentric granulomatosis, eosinophilic granulomatosis with polyangiitis, and pulmonary eosinophilia due to drugs or parasitic infection, and chronic pulmonary aspergillosis  (<a class="graphic graphic_table graphicRef76875" href="/d/graphic/76875.html" rel="external">table 1</a>). (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> – Complications of ABPA, while uncommon, include acute invasive pulmonary aspergillosis, aspergilloma, chronic invasive aspergillosis, and problems related to bronchiectasis (eg, recurrent infections, hemoptysis). (See <a class="local">'Complications'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2002; 110:685.</a></li><li><a class="nounderline abstract_t">Zander DS. Allergic bronchopulmonary aspergillosis: an overview. Arch Pathol Lab Med 2005; 129:924.</a></li><li><a class="nounderline abstract_t">Tillie-Leblond I, Tonnel AB. Allergic bronchopulmonary aspergillosis. Allergy 2005; 60:1004.</a></li><li><a class="nounderline abstract_t">Agarwal R. Allergic bronchopulmonary aspergillosis. Chest 2009; 135:805.</a></li><li><a class="nounderline abstract_t">Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37 Suppl 3:S225.</a></li><li><a class="nounderline abstract_t">Agarwal R. Burden and distinctive character of allergic bronchopulmonary aspergillosis in India. Mycopathologia 2014; 178:447.</a></li><li><a class="nounderline abstract_t">Becker JW, Burke W, McDonald G, et al. Prevalence of allergic bronchopulmonary aspergillosis and atopy in adult patients with cystic fibrosis. Chest 1996; 109:1536.</a></li><li><a class="nounderline abstract_t">Nepomuceno IB, Esrig S, Moss RB. Allergic bronchopulmonary aspergillosis in cystic fibrosis: role of atopy and response to itraconazole. Chest 1999; 115:364.</a></li><li><a class="nounderline abstract_t">Geller DE, Kaplowitz H, Light MJ, Colin AA. Allergic bronchopulmonary aspergillosis in cystic fibrosis: reported prevalence, regional distribution, and patient characteristics. Scientific Advisory Group, Investigators, and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Chest 1999; 116:639.</a></li><li><a class="nounderline abstract_t">Maturu VN, Agarwal R. Prevalence of Aspergillus sensitization and allergic bronchopulmonary aspergillosis in cystic fibrosis: systematic review and meta-analysis. Clin Exp Allergy 2015; 45:1765.</a></li><li><a class="nounderline abstract_t">Eppinger TM, Greenberger PA, White DA, et al. Sensitization to Aspergillus species in the congenital neutrophil disorders chronic granulomatous disease and hyper-IgE syndrome. J Allergy Clin Immunol 1999; 104:1265.</a></li><li><a class="nounderline abstract_t">Verleden GM, Dupont LJ, Van Raemdonck DE. ABPA: does it really exist after lung transplantation? J Heart Lung Transplant 2009; 28:1239.</a></li><li><a class="nounderline abstract_t">Cerceo E, Kotloff RM, Hadjiliadis D, et al. Central airways obstruction due to Aspergillus fumigatus after lung transplantation. J Heart Lung Transplant 2009; 28:515.</a></li><li><a class="nounderline abstract_t">Riscili BP, Wood KL. Noninvasive pulmonary Aspergillus infections. Clin Chest Med 2009; 30:315.</a></li><li class="breakAll">Cordier J-F, Cottin V. Eosinophilic pneumonias. In: Interstitial Lung Disease, 5th, Schwarz MI, King TE Jr. (Eds), People's Medical Publishing House-USA, Shelton, CT 2011. p.833.</li><li><a class="nounderline abstract_t">Beaumont F, Kauffman HF, de Monchy JG, et al. Volumetric aerobiological survey of conidial fungi in the North-East Netherlands. II. Comparison of aerobiological data and skin tests with mould extracts in an asthmatic population. Allergy 1985; 40:181.</a></li><li><a class="nounderline abstract_t">Greenberger PA, Smith LJ, Hsu CC, et al. Analysis of bronchoalveolar lavage in allergic bronchopulmonary aspergillosis: divergent responses of antigen-specific antibodies and total IgE. J Allergy Clin Immunol 1988; 82:164.</a></li><li><a class="nounderline abstract_t">Kauffman HF, Tomee JF, van der Werf TS, et al. Review of fungus-induced asthmatic reactions. Am J Respir Crit Care Med 1995; 151:2109.</a></li><li><a class="nounderline abstract_t">Chauhan B, Knutsen Ap, Hutcheson PS, et al. T cell subsets, epitope mapping, and HLA-restriction in patients with allergic bronchopulmonary aspergillosis. J Clin Invest 1996; 97:2324.</a></li><li><a class="nounderline abstract_t">Overton NL, Denning DW, Bowyer P, Simpson A. Genetic susceptibility to allergic bronchopulmonary aspergillosis in asthma: a genetic association study. Allergy Asthma Clin Immunol 2016; 12:47.</a></li><li><a class="nounderline abstract_t">Kreindler JL, Steele C, Nguyen N, et al. Vitamin D3 attenuates Th2 responses to Aspergillus fumigatus mounted by CD4+ T cells from cystic fibrosis patients with allergic bronchopulmonary aspergillosis. J Clin Invest 2010; 120:3242.</a></li><li><a class="nounderline abstract_t">Gibson PG, Wark PA, Simpson JL, et al. Induced sputum IL-8 gene expression, neutrophil influx and MMP-9 in allergic bronchopulmonary aspergillosis. Eur Respir J 2003; 21:582.</a></li><li><a class="nounderline abstract_t">Muniz VS, Silva JC, Braga YAV, et al. Eosinophils release extracellular DNA traps in response to Aspergillus fumigatus. J Allergy Clin Immunol 2018; 141:571.</a></li><li><a class="nounderline abstract_t">Bacher P, Hohnstein T, Beerbaum E, et al. Human Anti-fungal Th17 Immunity and Pathology Rely on Cross-Reactivity against Candida albicans. Cell 2019; 176:1340.</a></li><li><a class="nounderline abstract_t">Agarwal R, Aggarwal AN, Gupta D, Jindal SK. Aspergillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with bronchial asthma: systematic review and meta-analysis. Int J Tuberc Lung Dis 2009; 13:936.</a></li><li><a class="nounderline abstract_t">Agarwal R, Chakrabarti A, Shah A, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy 2013; 43:850.</a></li><li><a class="nounderline abstract_t">Schubert MS. Allergic fungal sinusitis: pathophysiology, diagnosis and management. Med Mycol 2009; 47 Suppl 1:S324.</a></li><li><a class="nounderline abstract_t">Natarajan S, Subramanian P. Allergic bronchopulmonary aspergillosis: A clinical review of 24 patients: Are we right in frequent serologic monitoring? Ann Thorac Med 2014; 9:216.</a></li><li><a class="nounderline abstract_t">Agarwal R, Gupta D, Aggarwal AN, et al. Allergic bronchopulmonary aspergillosis: lessons from 126 patients attending a chest clinic in north India. Chest 2006; 130:442.</a></li><li><a class="nounderline abstract_t">Agarwal R, Aggarwal AN, Sehgal IS, et al. Performance of serum galactomannan in patients with allergic bronchopulmonary aspergillosis. Mycoses 2015; 58:408.</a></li><li><a class="nounderline abstract_t">Buckingham SJ, Hansell DM. Aspergillus in the lung: diverse and coincident forms. Eur Radiol 2003; 13:1786.</a></li><li><a class="nounderline abstract_t">Reiff DB, Wells AU, Carr DH, et al. CT findings in bronchiectasis: limited value in distinguishing between idiopathic and specific types. AJR Am J Roentgenol 1995; 165:261.</a></li><li><a class="nounderline abstract_t">Johkoh T, Müller NL, Akira M, et al. Eosinophilic lung diseases: diagnostic accuracy of thin-section CT in 111 patients. Radiology 2000; 216:773.</a></li><li><a class="nounderline abstract_t">Ward S, Heyneman L, Lee MJ, et al. Accuracy of CT in the diagnosis of allergic bronchopulmonary aspergillosis in asthmatic patients. AJR Am J Roentgenol 1999; 173:937.</a></li><li><a class="nounderline abstract_t">Kaur M, Sudan DS. Allergic Bronchopulmonary Aspergillosis (ABPA)-The High Resolution Computed Tomography (HRCT) Chest Imaging Scenario. J Clin Diagn Res 2014; 8:RC05.</a></li><li><a class="nounderline abstract_t">Mitchell TA, Hamilos DL, Lynch DA, Newell JD. Distribution and severity of bronchiectasis in allergic bronchopulmonary aspergillosis (ABPA). J Asthma 2000; 37:65.</a></li><li><a class="nounderline abstract_t">Agarwal R, Gupta D, Aggarwal AN, et al. Clinical significance of hyperattenuating mucoid impaction in allergic bronchopulmonary aspergillosis: an analysis of 155 patients. Chest 2007; 132:1183.</a></li><li><a class="nounderline abstract_t">Greenberger PA. When to suspect and work up allergic bronchopulmonary aspergillosis. Ann Allergy Asthma Immunol 2013; 111:1.</a></li><li><a class="nounderline abstract_t">Agarwal R, Khan A, Gupta D, et al. An alternate method of classifying allergic bronchopulmonary aspergillosis based on high-attenuation mucus. PLoS One 2010; 5:e15346.</a></li><li><a class="nounderline abstract_t">Malo JL, Longbottom J, Mitchell J, et al. Studies in chronic allergic bronchopulmonary aspergillosis. 3. Immunological findings. Thorax 1977; 32:269.</a></li><li><a class="nounderline abstract_t">Greenberger PA, Patterson R. Diagnosis and management of allergic bronchopulmonary aspergillosis. Ann Allergy 1986; 56:444.</a></li><li><a class="nounderline abstract_t">Agarwal R, Sehgal IS, Dhooria S, Aggarwal AN. Developments in the diagnosis and treatment of allergic bronchopulmonary aspergillosis. Expert Rev Respir Med 2016; 10:1317.</a></li><li><a class="nounderline abstract_t">Glancy JJ, Elder JL, McAleer R. Allergic bronchopulmonary fungal disease without clinical asthma. Thorax 1981; 36:345.</a></li><li><a class="nounderline abstract_t">Berkin KE, Vernon DR, Kerr JW. Lung collapse caused by allergic bronchopulmonary aspergillosis in non-asthmatic patients. Br Med J (Clin Res Ed) 1982; 285:552.</a></li><li><a class="nounderline abstract_t">Muthu V, Sehgal IS, Prasad KT, et al. Allergic bronchopulmonary aspergillosis (ABPA) sans asthma: A distinct subset of ABPA with a lesser risk of exacerbation. Med Mycol 2020; 58:260.</a></li><li><a class="nounderline abstract_t">Harada K, Oguma T, Saito A, et al. Concordance between Aspergillus-specific precipitating antibody and IgG in allergic bronchopulmonary aspergillosis. Allergol Int 2018; 67S:S12.</a></li><li><a class="nounderline abstract_t">Agarwal R, Dua D, Choudhary H, et al. Role of Aspergillus fumigatus-specific IgG in diagnosis and monitoring treatment response in allergic bronchopulmonary aspergillosis. Mycoses 2017; 60:33.</a></li><li><a class="nounderline abstract_t">Dumollard C, Bailly S, Perriot S, et al. Prospective Evaluation of a New Aspergillus IgG Enzyme Immunoassay Kit for Diagnosis of Chronic and Allergic Pulmonary Aspergillosis. J Clin Microbiol 2016; 54:1236.</a></li><li><a class="nounderline abstract_t">Sehgal IS, Choudhary H, Dhooria S, et al. Prevalence of sensitization to Aspergillus flavus in patients with allergic bronchopulmonary aspergillosis. Med Mycol 2019; 57:270.</a></li><li><a class="nounderline abstract_t">Lake FR, Froudist JH, McAleer R, et al. Allergic bronchopulmonary fungal disease caused by Bipolaris and Curvularia. Aust N Z J Med 1991; 21:871.</a></li><li><a class="nounderline abstract_t">Chowdhary A, Agarwal K, Kathuria S, et al. Allergic bronchopulmonary mycosis due to fungi other than Aspergillus: a global overview. Crit Rev Microbiol 2014; 40:30.</a></li><li><a class="nounderline abstract_t">Pihet M, Carrere J, Cimon B, et al. Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis--a review. Med Mycol 2009; 47:387.</a></li><li><a class="nounderline abstract_t">Walicka-Serzysko K, Sands D. The clinical presentations of pulmonary aspergillosis in children with cystic fibrosis - preliminary report. Dev Period Med 2015; 19:66.</a></li><li><a class="nounderline abstract_t">Gernez Y, Waters J, Mirković B, et al. Blood basophil activation is a reliable biomarker of allergic bronchopulmonary aspergillosis in cystic fibrosis. Eur Respir J 2016; 47:177.</a></li><li><a class="nounderline abstract_t">Mirković B, Lavelle GM, Azim AA, et al. The basophil surface marker CD203c identifies Aspergillus species sensitization in patients with cystic fibrosis. J Allergy Clin Immunol 2016; 137:436.</a></li><li><a class="nounderline abstract_t">Katelari A, Tzanoudaki M, Noni M, et al. The role of basophil activation test in allergic bronchopulmonary aspergillosis and Aspergillus fumigatus sensitization in cystic fibrosis patients. J Cyst Fibros 2016; 15:587.</a></li><li><a class="nounderline abstract_t">Fitzsimons EJ, Aris R, Patterson R. Recurrence of allergic bronchopulmonary aspergillosis in the posttransplant lungs of a cystic fibrosis patient. Chest 1997; 112:281.</a></li><li><a class="nounderline abstract_t">Greenberger PA, Patterson R. Allergic bronchopulmonary aspergillosis and the evaluation of the patient with asthma. J Allergy Clin Immunol 1988; 81:646.</a></li><li><a class="nounderline abstract_t">Schwartz HJ, Citron KM, Chester EH, et al. A comparison of the prevalence of sensitization to Aspergillus antigens among asthmatics in Cleveland and London. J Allergy Clin Immunol 1978; 62:9.</a></li><li><a class="nounderline abstract_t">Schwartz HJ, Greenberger PA. The prevalence of allergic bronchopulmonary aspergillosis in patients with asthma, determined by serologic and radiologic criteria in patients at risk. J Lab Clin Med 1991; 117:138.</a></li><li><a class="nounderline abstract_t">Basich JE, Graves TS, Baz MN, et al. Allergic bronchopulmonary aspergillosis in corticosteroid-dependent asthmatics. J Allergy Clin Immunol 1981; 68:98.</a></li><li><a class="nounderline abstract_t">Eaton T, Garrett J, Milne D, et al. Allergic bronchopulmonary aspergillosis in the asthma clinic. A prospective evaluation of CT in the diagnostic algorithm. Chest 2000; 118:66.</a></li><li><a class="nounderline abstract_t">Bahous J, Malo JL, Paquin R, et al. Allergic bronchopulmonary aspergillosis and sensitization to Aspergillus fumigatus in chronic bronchiectasis in adults. Clin Allergy 1985; 15:571.</a></li><li><a class="nounderline abstract_t">Faux JA, Shale DJ, Lane DJ. Precipitins and specific IgG antibody to Aspergillus fumigatus in a chest unit population. Thorax 1992; 47:48.</a></li><li><a class="nounderline abstract_t">Neeld DA, Goodman LR, Gurney JW, et al. Computerized tomography in the evaluation of allergic bronchopulmonary aspergillosis. Am Rev Respir Dis 1990; 142:1200.</a></li><li><a class="nounderline abstract_t">Paganin F, Trussard V, Seneterre E, et al. Chest radiography and high resolution computed tomography of the lungs in asthma. Am Rev Respir Dis 1992; 146:1084.</a></li><li><a class="nounderline abstract_t">Angus RM, Davies ML, Cowan MD, et al. Computed tomographic scanning of the lung in patients with allergic bronchopulmonary aspergillosis and in asthmatic patients with a positive skin test to Aspergillus fumigatus. Thorax 1994; 49:586.</a></li><li><a class="nounderline abstract_t">Maturu VN, Agarwal R. Acute Invasive Pulmonary Aspergillosis Complicating Allergic Bronchopulmonary Aspergillosis: Case Report and Systematic Review. Mycopathologia 2015; 180:209.</a></li><li><a class="nounderline abstract_t">Shah A, Panjabi C. Contemporaneous occurrence of allergic bronchopulmonary aspergillosis, allergic Aspergillus sinusitis, and aspergilloma. Ann Allergy Asthma Immunol 2006; 96:874.</a></li><li><a class="nounderline abstract_t">Lowes D, Chishimba L, Greaves M, Denning DW. Development of chronic pulmonary aspergillosis in adult asthmatics with ABPA. Respir Med 2015; 109:1509.</a></li></ol></div><div id="topicVersionRevision">Topic 2419 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12417875" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Allergic bronchopulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15974818" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Allergic bronchopulmonary aspergillosis: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15969680" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Allergic bronchopulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19265090" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Allergic bronchopulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12975753" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24947170" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Burden and distinctive character of allergic bronchopulmonary aspergillosis in India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8769507" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prevalence of allergic bronchopulmonary aspergillosis and atopy in adult patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10027433" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Allergic bronchopulmonary aspergillosis in cystic fibrosis: role of atopy and response to itraconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10492265" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Allergic bronchopulmonary aspergillosis in cystic fibrosis: reported prevalence, regional distribution, and patient characteristics. Scientific Advisory Group, Investigators, and Coordinators of the Epidemiologic Study of Cystic Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26177981" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prevalence of Aspergillus sensitization and allergic bronchopulmonary aspergillosis in cystic fibrosis: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10589011" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Sensitization to Aspergillus species in the congenital neutrophil disorders chronic granulomatous disease and hyper-IgE syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19783167" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : ABPA: does it really exist after lung transplantation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19416784" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Central airways obstruction due to Aspergillus fumigatus after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19375638" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Noninvasive pulmonary Aspergillus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19375638" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Noninvasive pulmonary Aspergillus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4039540" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Volumetric aerobiological survey of conidial fungi in the North-East Netherlands. II. Comparison of aerobiological data and skin tests with mould extracts in an asthmatic population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3042837" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Analysis of bronchoalveolar lavage in allergic bronchopulmonary aspergillosis: divergent responses of antigen-specific antibodies and total IgE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7767565" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Review of fungus-induced asthmatic reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8636413" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : T cell subsets, epitope mapping, and HLA-restriction in patients with allergic bronchopulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27708669" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Genetic susceptibility to allergic bronchopulmonary aspergillosis in asthma: a genetic association study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20714107" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Vitamin D3 attenuates Th2 responses to Aspergillus fumigatus mounted by CD4+ T cells from cystic fibrosis patients with allergic bronchopulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12762339" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Induced sputum IL-8 gene expression, neutrophil influx and MMP-9 in allergic bronchopulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28943470" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Eosinophils release extracellular DNA traps in response to Aspergillus fumigatus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30799037" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Human Anti-fungal Th17 Immunity and Pathology Rely on Cross-Reactivity against Candida albicans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19723372" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Aspergillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with bronchial asthma: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23889240" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19330659" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Allergic fungal sinusitis: pathophysiology, diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25276240" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Allergic bronchopulmonary aspergillosis: A clinical review of 24 patients: Are we right in frequent serologic monitoring?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16899843" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Allergic bronchopulmonary aspergillosis: lessons from 126 patients attending a chest clinic in north India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25959212" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Performance of serum galactomannan in patients with allergic bronchopulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12783174" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Aspergillus in the lung: diverse and coincident forms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7618537" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : CT findings in bronchiectasis: limited value in distinguishing between idiopathic and specific types.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10966710" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Eosinophilic lung diseases: diagnostic accuracy of thin-section CT in 111 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10511153" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Accuracy of CT in the diagnosis of allergic bronchopulmonary aspergillosis in asthmatic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25121041" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Allergic Bronchopulmonary Aspergillosis (ABPA)-The High Resolution Computed Tomography (HRCT) Chest Imaging Scenario.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10724299" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Distribution and severity of bronchiectasis in allergic bronchopulmonary aspergillosis (ABPA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17646221" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Clinical significance of hyperattenuating mucoid impaction in allergic bronchopulmonary aspergillosis: an analysis of 155 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23806451" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : When to suspect and work up allergic bronchopulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21179536" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : An alternate method of classifying allergic bronchopulmonary aspergillosis based on high-attenuation mucus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/329461" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Studies in chronic allergic bronchopulmonary aspergillosis. 3. Immunological findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3521402" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Diagnosis and management of allergic bronchopulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27744712" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Developments in the diagnosis and treatment of allergic bronchopulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7314002" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Allergic bronchopulmonary fungal disease without clinical asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6809169" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Lung collapse caused by allergic bronchopulmonary aspergillosis in non-asthmatic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31111905" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Allergic bronchopulmonary aspergillosis (ABPA) sans asthma: A distinct subset of ABPA with a lesser risk of exacerbation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29773475" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Concordance between Aspergillus-specific precipitating antibody and IgG in allergic bronchopulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27523578" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Role of Aspergillus fumigatus-specific IgG in diagnosis and monitoring treatment response in allergic bronchopulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26888904" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Prospective Evaluation of a New Aspergillus IgG Enzyme Immunoassay Kit for Diagnosis of Chronic and Allergic Pulmonary Aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29566248" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Prevalence of sensitization to Aspergillus flavus in patients with allergic bronchopulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1818547" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Allergic bronchopulmonary fungal disease caused by Bipolaris and Curvularia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23383677" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Allergic bronchopulmonary mycosis due to fungi other than Aspergillus: a global overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19107638" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis--a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26003072" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The clinical presentations of pulmonary aspergillosis in children with cystic fibrosis - preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26585435" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Blood basophil activation is a reliable biomarker of allergic bronchopulmonary aspergillosis in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26388311" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The basophil surface marker CD203c identifies Aspergillus species sensitization in patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26922860" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The role of basophil activation test in allergic bronchopulmonary aspergillosis and Aspergillus fumigatus sensitization in cystic fibrosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9228393" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Recurrence of allergic bronchopulmonary aspergillosis in the posttransplant lungs of a cystic fibrosis patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3356845" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Allergic bronchopulmonary aspergillosis and the evaluation of the patient with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/350936" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A comparison of the prevalence of sensitization to Aspergillus antigens among asthmatics in Cleveland and London.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1993855" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The prevalence of allergic bronchopulmonary aspergillosis in patients with asthma, determined by serologic and radiologic criteria in patients at risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7252001" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Allergic bronchopulmonary aspergillosis in corticosteroid-dependent asthmatics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10893361" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Allergic bronchopulmonary aspergillosis in the asthma clinic. A prospective evaluation of CT in the diagnostic algorithm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3907888" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Allergic bronchopulmonary aspergillosis and sensitization to Aspergillus fumigatus in chronic bronchiectasis in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1539145" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Precipitins and specific IgG antibody to Aspergillus fumigatus in a chest unit population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2240844" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Computerized tomography in the evaluation of allergic bronchopulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1416399" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Chest radiography and high resolution computed tomography of the lungs in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8016796" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Computed tomographic scanning of the lung in patients with allergic bronchopulmonary aspergillosis and in asthmatic patients with a positive skin test to Aspergillus fumigatus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26045286" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Acute Invasive Pulmonary Aspergillosis Complicating Allergic Bronchopulmonary Aspergillosis: Case Report and Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16802778" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Contemporaneous occurrence of allergic bronchopulmonary aspergillosis, allergic Aspergillus sinusitis, and aspergilloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26507434" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Development of chronic pulmonary aspergillosis in adult asthmatics with ABPA.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
